- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00285675
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
A Continuation Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multicenter, open-label trial of DN-101 and docetaxel combination therapy to monitor the safety of ongoing DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 or DN101-004 studies. For subjects enrolled in DN101-002 study, only subjects randomized to the DN-101 treatment arm and are currently receiving study drug (including subjects on study suspension / holiday) will be included in the current study. For subjects enrolled in DN101-004 study, only subjects who are receiving study treatment will be included.
Safety will be assessed throughout the study. Safety evaluations will consist of a modified physical exam (vital signs and weight) and laboratory assessments. Modified physical exam should be performed at the beginning of each treatment cycle. Docetaxel-related laboratory assessments will be performed per standard of care as noted in the labeling. DN-101-related laboratory assessments for serum calcium and serum creatinine will be performed at the beginning of each treatment cycle. Clinically significant abnormal laboratory values will be reported as adverse events.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute, Department of Medicine
-
-
-
-
California
-
Berkeley, California, United States, 94704
- Alta Bates Comprehensive Cancer Center
-
San Francisco, California, United States, 94115
- Pacific Hematology Oncology Associates
-
Vallejo, California, United States, 94589
- Kaiser Permanente Medical Group, Northern California
-
-
New York
-
New York, New York, United States, 10032
- Columbia Presbyterian Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Piedmont Hematology Oncology Associates
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Oregon Health & Science University
-
Portland, Oregon, United States, 97227
- NW Kaiser Permanente Portland
-
Portland, Oregon, United States, 97239-3098
- Alta Bates Comprehensive Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232-1305
- University of Pittsburgh,William Copper Ambulatory Care, Pavillion Hellman Cancer Center
-
-
Texas
-
Tyler, Texas, United States, 75702
- Tyler Cancer Center
-
-
Washington
-
Vancouver, Washington, United States, 98684
- Northwest Cancer Specialists Vancouver Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prior participation in DN101-002 or DN101-004 studies, where the subject received at least one dose of DN-101
- Able and willing to give written informed consent
Exclusion Criteria:
- Disease progression or unacceptable toxicity while previously enrolled in DN101-002 or DN101-004 studies
- Prior investigational therapy other than DN-101 within 30 days of enrollment
- Known hypersensitivity to calcitriol
- Pregnancy (women of childbearing potential only)
- Greater than 90 days has elapsed from termination of DN101-002 or DN101-004 studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Prostatic Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Micronutrients
- Membrane Transport Modulators
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vasoconstrictor Agents
- Calcium Channel Agonists
- Calcitriol
Other Study ID Numbers
- 011-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer (NSCLC)
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell CarcinomaUnited States
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Heather WakeleeNovartis; Genentech, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IVUnited States
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
AmgenParexelWithdrawnMetastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
Clinical Trials on DN-101 (calcitriol) - Drug
-
NovaceaUnknownMyelodysplastic SyndromeUnited States
-
NovaceaCompletedNeoplasmsUnited States
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Microbion CorporationUniversity of Pennsylvania; University of California, San Francisco; Medpace,... and other collaboratorsCompletedBacterial InfectionUnited States
-
ViiV HealthcareActive, not recruiting
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; Taiho Oncology, Inc.RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Joseph L. Kuti, PharmDCubist Pharmaceuticals LLC; Indiana University Health; University of North Carolina and other collaboratorsCompletedCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Pseudomonas Aeruginosa InfectionUnited States
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Merck Sharp & Dohme LLCCompletedOther Infectious DiseasesUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityTerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic LeukemiaUnited States